SARASOTA, Fla., Aug. 31, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that Neil J. Campbell, MA, MBA, and Leonard DeRoma, MBA, will be joining the company's Board of Directors. Mr. Campbell has over 25 years as a global C-level serial entrepreneur executive, academic professor, and investment partner. He has experience from concept through commercialization of over 300 products and services to-date. Mr. DeRoma has 40 years of experience in senior financial institution positions, and is founder of Invictus Group LLC, a bank advisory firm, and Chief Executive Officer of Wildwood Capital LLC, a small boutique advisory firm focused on strategic advice, mergers and acquisitions, and fund raising for small and middle market companies. They will be joining Lakewood-Amedex's current board members: Steve Parkinson, Executive Director and Chairman, and Geoffrey F. Cox, PhD.
Steve Parkinson, Lakewood-Amedex's CEO and President, said, "We are thrilled to have Neil and Lenny join our Board of Directors. Their depth of experience and leadership expertise in both the commercial operations and financing of development-stage biopharmaceutical companies will lend an essential perspective to our board. With the upcoming completion of our Phase 1/2a clinical trial using our topical Bisphosphocin Nu-3 for infected diabetic foot ulcers (DFU), their independent strategic insight will be crucial to successfully guiding our Bisphosphocin pipeline through to potential FDA approval."
"I look forward to helping advance this vital new class of antimicrobials to market," said Neil J. Campbell. "Both Nu-3 and Nu-8 have shown promising results against clinically relevant and antibiotic resistant bacterial strains responsible for life-threatening infections, including E. coli and P. aeruginosa, responsible for a majority of CAUTI and recurrent bladder infections and also prevalent in DFU infections. Ensuring the success of these novel antimicrobial drug candidates is an important step in fighting the growing global threat of antibiotic resistance."
Leonard DeRoma added, "I am pleased be an advisor to Lakewood-Amedex for both their strategic direction and fund-raising activities. Bringing this new class of antimicrobials with broad-spectrum activity against bacteria, yeast, and certain fungi to market is an important initiative for today's global healthcare community."
Mr. Campbell currently sits on various company boards, private equity, venture capital, and government investment committees, and serves as the managing general partner of Dog River Ventures, a private investment group in science and technology. Previously, he raised over $265 million while serving four different biotechnology companies: as CEO of Helomics Corporation, a personalized oncology healthcare company, President and CEO of SuperNova Diagnostics®, Inc, a privately-held global diagnostics company, President & COO/CEO for EntreMed Pharmaceuticals, a clinical-stage pharmaceutical company committed to developing a selective angiogenic kinase inhibitor for the treatment of cancer, and Senior Director of Commercial Development for Celera Genomics, where he built global genomic & proteomic businesses around the human genome project. He has also served as Operating Partner of Healthcare Royalty Partners, a private equity investment firm, CEO and Founder of Mosaigen, a privately-held commercial development company, and General Partner for Endeavour Capital, an Asia/Pacific private equity fund in the life sciences, cleantech and information communication technologies (ICT). He earned his BS at Norwich University, his MA and MBS at Webster University and is completing his doctorate at the University of Liverpool.
Mr. DeRoma has spent over 40 years in senior positions of major financial institutions including Citibank, Lehman Brothers, Barclays Capital and Keybank-McDonald Investments, managing large components of their domestic and foreign fixed-income trading, sales, derivatives, research, underwritings and foreign exchange businesses. He also served as the President of Barclay's U.S. securities business, was senior advisor to the U.S. Asset Liability Committee, and chaired the U.S. Credit and Risk Management Committee. He then founded Wildwood Capital LLC, and subsequently was a founding partner of Invictus Consulting Group, an advisory company oriented towards the strategic needs of community banks. He serves on the Board of Directors of TMMI, a video compression company and Trusted Networks, Inc., a software company focused on secured communications. Mr. DeRoma holds a Bachelor of Science in Electrical Engineering from the Massachusetts Institute of Technology and a Masters in Business Administration from the Harvard Business School.
About Lakewood-Amedex, Inc.
Lakewood-Amedex is a clinical stage pharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds. The Company's products and technology are covered by an extensive patent portfolio consisting of 74 granted and/or issued patents and 13 pending patent applications covering many major pharmaceutical markets. The Company's lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram-positive, gram-negative and antibiotic-resistant bacteria and is currently in Phase 1/2a clinical trials.
This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.
SOURCE Lakewood-Amedex Inc.